aluates Reports

$ 0.0

Automative

Global Spinal Muscular Atrophy (SMA) Drugs Market Research Report 2025

Published Date: June 2025

Report Code: QYRE-Auto-12A10127

Global Spinal Muscular Atrophy SMA Drugs Market Insights Forecast to 2028

BUY CHAPTERS

Global Spinal Muscular Atrophy (SMA) Drugs Market Research Report 2025

Code: QYRE-Auto-12A10127

Report

June 2025

Pages:64

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Biogen

Novartis

Genentech Inc

Spinal Muscular Atrophy (SMA) Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Spinal Muscular Atrophy (SMA) Drugs Market

The global market for Spinal Muscular Atrophy (SMA) Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Spinal Muscular Atrophy (SMA), also known as spinal muscular atrophy, is a type of disease in which the degeneration of motor neurons in the anterior horn of the spinal cord leads to muscle weakness and muscular atrophy.The Spinal muscular atrophy drugs Can effectively alleviate the symptoms of the disease.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Spinal Muscular Atrophy (SMA) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Spinal Muscular Atrophy (SMA) Drugs.

The Spinal Muscular Atrophy (SMA) Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Spinal Muscular Atrophy (SMA) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Spinal Muscular Atrophy (SMA) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Spinal Muscular Atrophy (SMA) Drugs Market Report

Report Metric	Details
Report Name	Spinal Muscular Atrophy (SMA) Drugs Market
CAGR	5%
Segment by Type	Oral Medicine Injection Medicine
Segment by Application	Baby Child Adult
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Biogen, Novartis, Genentech
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Spinal Muscular Atrophy (SMA) Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Spinal Muscular Atrophy (SMA) Drugs Market report?

Ans: The main players in the Spinal Muscular Atrophy (SMA) Drugs Market are Biogen, Novartis, Genentech

What are the Application segmentation covered in the Spinal Muscular Atrophy (SMA) Drugs Market report?

Ans: The Applications covered in the Spinal Muscular Atrophy (SMA) Drugs Market report are Baby, Child, Adult

What are the Type segmentation covered in the Spinal Muscular Atrophy (SMA) Drugs Market report?

Ans: The Types covered in the Spinal Muscular Atrophy (SMA) Drugs Market report are Oral Medicine, Injection Medicine

Recommended Reports

Rare Disease Drugs

Neurological Disorders

Neurodegenerative Diseases

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Oral Medicine

1.2.3 Injection Medicine

1.3 Market by Application

1.3.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Baby

1.3.3 Child

1.3.4 Adult

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Perspective (2020-2031)

2.2 Global Spinal Muscular Atrophy (SMA) Drugs Growth Trends by Region

2.2.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Spinal Muscular Atrophy (SMA) Drugs Historic Market Size by Region (2020-2025)

2.2.3 Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Region (2026-2031)

2.3 Spinal Muscular Atrophy (SMA) Drugs Market Dynamics

2.3.1 Spinal Muscular Atrophy (SMA) Drugs Industry Trends

2.3.2 Spinal Muscular Atrophy (SMA) Drugs Market Drivers

2.3.3 Spinal Muscular Atrophy (SMA) Drugs Market Challenges

2.3.4 Spinal Muscular Atrophy (SMA) Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Spinal Muscular Atrophy (SMA) Drugs Players by Revenue

3.1.1 Global Top Spinal Muscular Atrophy (SMA) Drugs Players by Revenue (2020-2025)

3.1.2 Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Players (2020-2025)

3.2 Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Spinal Muscular Atrophy (SMA) Drugs Revenue

3.4 Global Spinal Muscular Atrophy (SMA) Drugs Market Concentration Ratio

3.4.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Spinal Muscular Atrophy (SMA) Drugs Revenue in 2024

3.5 Global Key Players of Spinal Muscular Atrophy (SMA) Drugs Head office and Area Served

3.6 Global Key Players of Spinal Muscular Atrophy (SMA) Drugs, Product and Application

3.7 Global Key Players of Spinal Muscular Atrophy (SMA) Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Spinal Muscular Atrophy (SMA) Drugs Breakdown Data by Type

4.1 Global Spinal Muscular Atrophy (SMA) Drugs Historic Market Size by Type (2020-2025)

4.2 Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Type (2026-2031)

5 Spinal Muscular Atrophy (SMA) Drugs Breakdown Data by Application

5.1 Global Spinal Muscular Atrophy (SMA) Drugs Historic Market Size by Application (2020-2025)

5.2 Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Spinal Muscular Atrophy (SMA) Drugs Market Size (2020-2031)

6.2 North America Spinal Muscular Atrophy (SMA) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025)

6.4 North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size (2020-2031)

7.2 Europe Spinal Muscular Atrophy (SMA) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025)

7.4 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size (2020-2031)

8.2 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (2020-2025)

8.4 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size (2020-2031)

9.2 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025)

9.4 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size (2020-2031)

10.2 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025)

10.4 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Biogen

11.1.1 Biogen Company Details

11.1.2 Biogen Business Overview

11.1.3 Biogen Spinal Muscular Atrophy (SMA) Drugs Introduction

11.1.4 Biogen Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025)

11.1.5 Biogen Recent Development

11.2 Novartis

11.2.1 Novartis Company Details

11.2.2 Novartis Business Overview

11.2.3 Novartis Spinal Muscular Atrophy (SMA) Drugs Introduction

11.2.4 Novartis Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025)

11.2.5 Novartis Recent Development

11.3 Genentech

11.3.1 Genentech Company Details

11.3.2 Genentech Business Overview

11.3.3 Genentech Spinal Muscular Atrophy (SMA) Drugs Introduction

11.3.4 Genentech Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025)

11.3.5 Genentech Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Biogen

Novartis

Genentech Inc

List of Tables

Table 1. Global Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Oral Medicine

Table 3. Key Players of Injection Medicine

Table 4. Global Spinal Muscular Atrophy (SMA) Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Region (2020-2025)

Table 8. Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Region (2026-2031)

Table 10. Spinal Muscular Atrophy (SMA) Drugs Market Trends

Table 11. Spinal Muscular Atrophy (SMA) Drugs Market Drivers

Table 12. Spinal Muscular Atrophy (SMA) Drugs Market Challenges

Table 13. Spinal Muscular Atrophy (SMA) Drugs Market Restraints

Table 14. Global Spinal Muscular Atrophy (SMA) Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Players (2020-2025)

Table 16. Global Top Spinal Muscular Atrophy (SMA) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy (SMA) Drugs as of 2024)

Table 17. Ranking of Global Top Spinal Muscular Atrophy (SMA) Drugs Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Spinal Muscular Atrophy (SMA) Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Spinal Muscular Atrophy (SMA) Drugs, Headquarters and Area Served

Table 20. Global Key Players of Spinal Muscular Atrophy (SMA) Drugs, Product and Application

Table 21. Global Key Players of Spinal Muscular Atrophy (SMA) Drugs, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Type (2020-2025)

Table 25. Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Type (2026-2031)

Table 27. Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Application (2020-2025)

Table 29. Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Application (2026-2031)

Table 31. North America Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 46. Biogen Company Details

Table 47. Biogen Business Overview

Table 48. Biogen Spinal Muscular Atrophy (SMA) Drugs Product

Table 49. Biogen Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025) & (US$ Million)

Table 50. Biogen Recent Development

Table 51. Novartis Company Details

Table 52. Novartis Business Overview

Table 53. Novartis Spinal Muscular Atrophy (SMA) Drugs Product

Table 54. Novartis Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025) & (US$ Million)

Table 55. Novartis Recent Development

Table 56. Genentech Company Details

Table 57. Genentech Business Overview

Table 58. Genentech Spinal Muscular Atrophy (SMA) Drugs Product

Table 59. Genentech Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025) & (US$ Million)

Table 60. Genentech Recent Development

Table 61. Research Programs/Design for This Report

Table 62. Key Data Information from Secondary Sources

Table 63. Key Data Information from Primary Sources

Table 64. Authors List of This Report

List of Figures

Figure 1. Spinal Muscular Atrophy (SMA) Drugs Picture

Figure 2. Global Spinal Muscular Atrophy (SMA) Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Type: 2024 VS 2031

Figure 4. Oral Medicine Features

Figure 5. Injection Medicine Features

Figure 6. Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Application: 2024 VS 2031

Figure 8. Baby Case Studies

Figure 9. Child Case Studies

Figure 10. Adult Case Studies

Figure 11. Spinal Muscular Atrophy (SMA) Drugs Report Years Considered

Figure 12. Global Spinal Muscular Atrophy (SMA) Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Spinal Muscular Atrophy (SMA) Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Region: 2024 VS 2031

Figure 15. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Players in 2024

Figure 16. Global Top Spinal Muscular Atrophy (SMA) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy (SMA) Drugs as of 2024)

Figure 17. The Top 10 and 5 Players Market Share by Spinal Muscular Atrophy (SMA) Drugs Revenue in 2024

Figure 18. North America Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America Spinal Muscular Atrophy (SMA) Drugs Market Share by Country (2020-2031)

Figure 20. United States Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Spinal Muscular Atrophy (SMA) Drugs Market Share by Country (2020-2031)

Figure 24. Germany Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Share by Region (2020-2031)

Figure 32. China Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Share by Country (2020-2031)

Figure 40. Mexico Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Share by Country (2020-2031)

Figure 44. Turkey Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Biogen Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025)

Figure 48. Novartis Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025)

Figure 49. Genentech Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025)

Figure 50. Bottom-up and Top-down Approaches for This Report

Figure 51. Data Triangulation

Figure 52. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Spinal Muscular Atrophy SMA Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Spinal Muscular Atrophy Medicine Market Research Report 2025

Global Spinal Muscular Atrophy SMA Treatment Market Research Report 2024

Global Bulbospinal Muscular Atrophy Drugs Market Research Report 2024

Global Drugs for Spinal Muscular Atrophy SMA Market Research Report 2024

Spinal Muscular Atrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Injections for SMA Market Research Report 2024

Neurodegenerative Diseases Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Multiple System Atrophy Therapeutics Market Research Report 2024

Systemic Scleroderma Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Amyotrophic Lateral Sclerosis Device Market Research Report 2025

Skeletal Muscular Relaxants Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Becker Muscular Dystrophy Drug Market Research Report 2024

Myotonic Muscular Dystrophy DMD Treatments Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Stearyl Methacrylate SMA Market Research Report 2024

Global Neurodegenerative Disease Treatment Market Research Report 2024

Neurodegenerative Disease Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Duchenne Muscular Dystrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Neurodegenerative Disorder Therapeutics Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions